Drugs / BHP01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06348797 | Apr 2025 → Jun 2026 overdue | small cell lung carcinoma | Sichuan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHP01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06348797 ↗ |
| Modality | Cell therapy | “DLL3 Targeted α-PD-L1/4-1BB Modifying Chimeric Antigen Receptor T-cells” NCT06348797 ↗ |
| Route | Intravenous | “BHP01 was administered intravenous infusion at different cell dose levels.” NCT06348797 ↗ |